요약정보
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
- Resource Type
- Academic Journal
- Authors
- Dunbar AJ; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Myeloproliferative Neoplasm-Research Consortium.; Bowman RL; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Park YC; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; O'Connor K; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Izzo F; Weill Cornell Medical College of Cornell University, New York, New York.; New York Genome Center, New York, New York.; Myers RM; Weill Cornell Medical College of Cornell University, New York, New York.; New York Genome Center, New York, New York.; Karzai A; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Zaroogian Z; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Kim WJ; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Fernández-Maestre I; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.; Waarts MR; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.; Nazir A; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Xiao W; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Codilupi T; Department of Biomedicine, University of Basel, Basel, Switzerland.; Brodsky M; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Farina M; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, University of Brescia, ASST Spedali Civili di Brescia, Italy.; Cai L; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Cai SF; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Wang B; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; An W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; Yang JL; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.; Mowla S; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Eisman SE; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Hanasoge Somasundara AV; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Glass JL; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.; Mishra T; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Houston R; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Guzzardi E; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Martinez Benitez AR; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Viny AD; Division of Hematology and Oncology, Department of Medicine and Columbia Stem Cell Initiative, Columbia University Irving Medical Center, New York, New York.; Koche RP; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.; Meyer SC; Department of Biomedicine, University of Basel, Basel, Switzerland.; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Landau DA; Weill Cornell Medical College of Cornell University, New York, New York.; New York Genome Center, New York, New York.; Levine RL; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Myeloproliferative Neoplasm-Research Consortium.; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
- Source
- Publisher:
American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN:21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE - Subject
- Language
- English